[
  {
    "ts": null,
    "headline": "Johnson & Johnson’s Third Bankruptcy Case for Talc Lawsuits Thrown Out",
    "summary": "Johnson & Johnson’s Third Bankruptcy Case for Talc Lawsuits Thrown Out",
    "url": "https://finnhub.io/api/news?id=cdcbf512d57daeed92a09fb9f2701b08ed2e4e511168c190d8e438bc59476bb6",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743462120,
      "headline": "Johnson & Johnson’s Third Bankruptcy Case for Talc Lawsuits Thrown Out",
      "id": 133636056,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Johnson & Johnson’s Third Bankruptcy Case for Talc Lawsuits Thrown Out",
      "url": "https://finnhub.io/api/news?id=cdcbf512d57daeed92a09fb9f2701b08ed2e4e511168c190d8e438bc59476bb6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims",
    "summary": "Company has prevailed in 16 of 17 ovarian cases tried in the last 11 yearsCompany will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution...",
    "url": "https://finnhub.io/api/news?id=1f15462993199cb95470967b27d4bdb7b3dae863e11caab738f3b8a2d2deff9e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743459664,
      "headline": "Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims",
      "id": 133630752,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Company has prevailed in 16 of 17 ovarian cases tried in the last 11 yearsCompany will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution...",
      "url": "https://finnhub.io/api/news?id=1f15462993199cb95470967b27d4bdb7b3dae863e11caab738f3b8a2d2deff9e"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For April 2025",
    "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743437243,
      "headline": "Best Dividend Aristocrats For April 2025",
      "id": 133629387,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165465384/image_2165465384.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd"
    }
  },
  {
    "ts": null,
    "headline": "Are You Looking for a High-Growth Dividend Stock?",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=98403681fdba12520898e7dc2dcc91989bc9a8672e720e4b83c8e3f60013e5e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743435908,
      "headline": "Are You Looking for a High-Growth Dividend Stock?",
      "id": 133627788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=98403681fdba12520898e7dc2dcc91989bc9a8672e720e4b83c8e3f60013e5e9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
    "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive […]",
    "url": "https://finnhub.io/api/news?id=ff66259de9445c9854f6ab35b7f37f54840b209fdeac5ca1e0c8e497056b6424",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743428195,
      "headline": "Johnson & Johnson (JNJ): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
      "id": 133627789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive […]",
      "url": "https://finnhub.io/api/news?id=ff66259de9445c9854f6ab35b7f37f54840b209fdeac5ca1e0c8e497056b6424"
    }
  },
  {
    "ts": null,
    "headline": "RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar",
    "summary": "Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.",
    "url": "https://finnhub.io/api/news?id=2773ab609e61ad22906a0206ba8fbb465ae5eb55308723b21508b88063cb85c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743427800,
      "headline": "RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar",
      "id": 133627790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.",
      "url": "https://finnhub.io/api/news?id=2773ab609e61ad22906a0206ba8fbb465ae5eb55308723b21508b88063cb85c5"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.",
    "url": "https://finnhub.io/api/news?id=70cf00c471c5a3487d6fe002761b6cc0869dd2cd1109a7ecd7768740deb86de0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743426113,
      "headline": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
      "id": 133627791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.",
      "url": "https://finnhub.io/api/news?id=70cf00c471c5a3487d6fe002761b6cc0869dd2cd1109a7ecd7768740deb86de0"
    }
  }
]